Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01440504

Acronym

ABT737 exvivo

Enrollment

Registered

2011-09-26

Start date

2010-04-30

Completion date

2013-01-31

Last updated

2013-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

Cancer, Ovarian, chemotherapy, BH3-mimetic, platin, ex-vivo

Brief summary

The aim of the study is to quantify the ex vivo induction of apoptosis by ABT-737 + association platinum in samples exposed and demonstrate the value of this combination compared to the agents used alone.

Interventions

OTHERculture ex vivo with exposure to different therapeutic agents alone or in combination.

When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient aged over 18 years * Ovarian cancer patients with at least five tumor samples does not affect the diagnosis, based on other tumor masses * Surgery of any initial chemotherapy naive * Patient information and signed informed consent

Exclusion criteria

* A person deprived of liberty or under guardianship * Insufficient tumor samples of ovarian cancer.

Design outcomes

Primary

Measure	Time frame
rate of apoptotic cells	2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026